{"filings":[{"id":509238,"accession_number":"0001193125-26-229770","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-05-19T12:45:19+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics Announces Initial Phase 2 Data for Zovegalisib in Vascular Anomalies Showing 60% Response Rate","event_type":"other_material","confidence":"high","bullets":["60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.","89% of patients showed clinical improvement per investigator global impression at week 12; 79% per patient global impression.","Among 22 patients at 100mg and 300mg BID, no dose discontinuations; 9% had Grade 3+ TRAEs; no rash or stomatitis observed.","Expansion cohorts opened at 400mg QD and 300mg BID for adults/adolescents; pediatric dose-finding ongoing.","All 32 enrolled patients remained on treatment as of April 15, 2026 data cut-off; prior alpelisib/sirolimus use in 72%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95682,"accession_number":"0001193125-26-206398","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M","event_type":"earnings","confidence":"high","bullets":["FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.","Median PFS 11.1 months in heavily pre-treated patients; similar efficacy across kinase and non-kinase mutations.","Phase 3 1L trial of zovegalisib+atirmociclib expected early 2027; Pfizer to supply atirmociclib.","Initiated Phase 1/2 trial of RLY-8161, an NRAS-selective inhibitor, in NRAS-mutant solid tumors.","Cash, cash equivalents and investments $642.1M; net loss $73.3M ($0.41 per share) for Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":3000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95681,"accession_number":"0001193125-26-179404","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer","event_type":"other_material","confidence":"high","bullets":["ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.","Grade 3 hyperglycemia 0% despite 47% pre-diabetic; only 3% discontinued zovegalisib due to TRAEs.","Phase 3 trial of zovegalisib + atirmociclib + AI in 1L PIK3CA-mutated HR+/HER2- breast cancer expected to start early 2027.","Pfizer to supply atirmociclib and palbociclib for the trial; Relay retains full rights to zovegalisib.","Median follow-up 7.4 months; 77% of patients remain on study; median PFS not yet mature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108914,"accession_number":"0001193125-26-107312","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D","event_type":"other_material","confidence":"high","bullets":["Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.","Confirmed ORR 43% overall (15/35) and 52% in second-line patients (11/21).","Safety consistent with prior 600mg fasted; only 4 of 60 patients discontinued due to TRAEs.","Pharmacokinetics of 400mg BID fed comparable to 600mg BID fasted; most patients above IC80.","FDA Breakthrough Therapy designation already granted; Phase 3 ReDiscover-2 trial ongoing since mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108913,"accession_number":"0001193125-26-102178","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Relay Therapeutics adopts exclusive federal forum for securities claims","event_type":"other_material","confidence":"high","bullets":["Board approved second amended and restated bylaws effective March 6, 2026.","New exclusive forum provision requires securities law claims to be brought in federal district courts unless company consents otherwise.","Amendment covers claims under Securities Act of 1933 and Exchange Act of 1934.","No other material changes to bylaws were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108912,"accession_number":"0001193125-26-076617","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).","Cash, cash equivalents and investments $554.5M at Dec 31 2025, down from $781.3M; runway into 2029.","Revenue $7.0M in Q4 2025 (Elevar license) vs $0 in Q4 2024; full year revenue $15.4M.","Zovegalisib Phase 1/2 breast cancer data at ESMO TAT March 16 in 57 patients at Phase 3 dose.","Initial vascular anomalies data expected 1H 2026; pediatric cohort in ReInspire trial opened early."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":15355000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108911,"accession_number":"0001193125-26-034422","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay's zovegalisib granted FDA Breakthrough Therapy Designation for PIK3CA-mutant breast cancer","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to zovegalisib + fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6i.","Supported by ReDiscover trial data: 600mg BID fasted (N=52) and 400mg BID fed (N=57, Phase 3 dose) with comparable exposures.","Phase 3 dose 400mg BID fed data to be presented first at ESMO Targeted Anticancer Congress on March 16, 2026.","BTD aims to accelerate development and review; provides Fast Track features and enhanced FDA guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125373,"accession_number":"0001193125-25-269536","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors","event_type":"earnings","confidence":"high","bullets":["Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.","Cash, cash equivalents and investments $596.4M at Sep 30, 2025; expected to fund operations into 2029.","R&D expenses $68.3M, down from $76.6M YoY on streamlining and cost avoidance.","Board appointed Lonnel Coats and Habib Dable, former biotech CEOs, effective Nov 4, 2025.","Continued Phase 3 ReDiscover-2 trial and Phase 1/2 ReInspire trial in vascular malformations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":8355000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142096,"accession_number":"0000950170-25-105022","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial","event_type":"earnings","confidence":"high","bullets":["Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.","Cash, equivalents and investments $656.8M, expected to fund operations into 2029.","RLY-2608 + fulvestrant Phase 1b data: 10.3-month median PFS, 39% ORR in PI3Kα-mutated HR+/HER2- mBC.","Initiated Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant vs capivasertib + fulvestrant.","R&D expenses decreased to $63.9M from $92.0M due to streamlining and license agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":8355000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160068,"accession_number":"0001193125-25-139146","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns","event_type":"leadership","confidence":"high","bullets":["Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.","Claire Mazumdar, Ph.D., appointed as Class III director and Audit Committee chair effective June 9, 2025.","Dr. Mazumdar is founding CEO of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company.","She received an initial option to purchase 421,241 shares at $3.36/share, vesting monthly over three years.","Board determined Dr. Mazumdar is independent under Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160067,"accession_number":"0001193125-25-137162","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Relay Therapeutics stockholders elect directors and approve auditor at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["Alexis Borisy elected class II director with 80.7M votes for, 43.0M withheld.","Mark Murcko elected class II director with 79.5M votes for, 44.2M withheld.","Non-binding advisory vote on executive compensation approved: 69.7M for, 53.9M against.","Ratification of Ernst & Young as auditor for FY2025 passed with 142.2M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160066,"accession_number":"0001193125-25-134908","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Relay Therapeutics terminates Binney St lease early, signs Kendall Square lease; saves ~$16M in rent","event_type":"other_material","confidence":"high","bullets":["Paid $2.5M modification fee and transferred FF&E to landlord to terminate Binney St lease early.","Paid $3.5M relocation fee for new 12,190 sq ft office at One Kendall Square, Cambridge.","Combined lease changes reduce total rent expense by ~$16M over remaining lease terms.","Continues to lease 41,474 sq ft at 60 Hampshire St (HQ) through June 2032.","Binney St lease originally set to expire April 2029; early termination tied to Kendall Square possession."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}